Vertex Pharmaceuticals (VRTX) Net Cash Flow (2009 - 2026)

Vertex Pharmaceuticals' Net Cash Flow history runs 18 years deep, the most recent figure standing at $457.4 million for Q1 2026.

• On a quarterly basis, Net Cash Flow rose 453.08% year-over-year to $457.4 million in Q1 2026; TTM through Mar 2026 was $799.4 million, a 117.81% increase from a year earlier, with the FY2025 full-year figure at $424.7 million, up 107.38% from the prior year.
• Net Cash Flow climbed to $457.4 million in Q1 2026 per VRTX's latest filing, from $132.7 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $1.3 billion in Q4 2022 and bottomed at -$4.6 billion in Q2 2024.
• The 5-year median for Net Cash Flow is $239.4 million (2025), against an average of -$76.5 million.
• Across the five-year window, Net Cash Flow surged 558.1% in 2022 and slumped 639.74% in 2024, its largest moves.
• Year by year, Net Cash Flow stood at $1.3 billion in 2022, then sank by 159.63% to -$771.7 million in 2023, then climbed by 18.54% to -$628.6 million in 2024, then soared by 121.11% to $132.7 million in 2025, then jumped by 244.69% to $457.4 million in 2026.
• Per Business Quant, the three latest VRTX Net Cash Flow figures stand at $457.4 million (Q1 2026), $132.7 million (Q4 2025), and -$30.1 million (Q3 2025).